Austedo

Chemical Namedeutetrabenazine
Dosage FormTablet (oral; 6 mg, 9 mg, 12 mg)
Drug ClassInhibitors
SystemMusculoskeletal
CompanyTeva Pharmaceuticals USA, Inc.
Approval Year2017

Indication

  • To treat chorea associated with Huntington’s disease.
  • To treat tardive dyskinesia in adults.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Austedo (Deutetrabenazine ) Prescribing Information 2017Teva Pharmaceuticals USA, Inc., Parsippany, NJ
Document TitleYearSource
International guidelines for the treatment of Huntington's disease. 2019Frontiers in Neurology